KCT0000705进行中（未招募）未知
Randomized, double-blind, active-controlled, multi-center phase II clinical trial to investigate the safety, tolerability and efficacy of YH1885L in patients with non-erosive reflux disease(NERD)
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- Yuhan
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •subjects who signed written informed consent form
- •- more than 20 yr subject
- •- subjects who agree the use of medically accepted birth control during trial
- •- grade N, M by EGD test
- •- subject who experience 2 day out of 1 week during recent 1 month
- •- subject who experience 2 day out of 1 week during run-in period
排除标准
- •- Subjects who can write the diary by himself, herself
- •- Pregnant woman, breastfeeding woman
- •- Allgeric or intolerabiliy to revaprazan or esomeprazole
- •- Feeling of heavy stomach, distention
- •- Surgery history in stomach or esophagus
- •- Active medical history of stomach, esophagus area
- •- other system disorder which can disturb this trial
- •- Hep B, C virus, HIV carrier or patients
- •- Past history of malignant tumor
- •- Any psychiatric past or current history
- •- Abnormal lab test
- •- Abnormal ecg test
- •- Zollinger-ellison disease
- •- Current or past history of substance, drug abuse
- •- Subject who should regulary takes medication which can disturb this trial
研究者
相似试验
进行中（未招募）
不适用
Randomized, active-controlled, double-blind, parallel design study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to three times-per-week prophylaxis with rFVIII-FS in previously treated patients with severe hemophilia A. - NDSevere hemophilia AMedDRA version: 9.1Level: LLTClassification code 10056493Term: Haemophilia A without inhibitorsEUCTR2007-003718-32-ITBAYER250
进行中（未招募）
1 期
Randomized, active-controlled, double-blind, parallel design study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to three times-per-week prophylaxis with rFVIII-FS in previously treated patients with severe hemophilia AHemophilia AEUCTR2007-003718-32-NOBayer HealthCare AG250
进行中（未招募）
不适用
Randomized, active-controlled, double-blind, parallel design study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to three times-per-week prophylaxis with rFVIII-FS in previously treated patients with severe hemophilia AHemophilia AEUCTR2007-003718-32-DKBayer HealthCare AG100
尚未招募
2 期
Randomized, active-controlled, double-blind, parallel design study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to three times-per-week prophylaxis with rFVIII-FS in previously treated patients with severe hemophilia A10064477Hemophilia ANL-OMON33645Bayer10
进行中（未招募）
1 期
Randomized, active-controlled, double-blind, parallel design study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to three times-per-week prophylaxis with rFVIII-FS in previously treated patients with severe hemophilia AMedDRA version: 9.1Level: LLTClassification code 10060613Term: Hemophilia A (Factor VIII)MedDRA version: 9.1Level: LLTClassification code 10018937Term: Haemophilia AHemophilia AEUCTR2007-003718-32-FRBayer HealthCare AG143